TABLE 5.
Pathology | Interaction | Group | Beta | 99% CI | SE | p Value |
---|---|---|---|---|---|---|
Braak stage | Thal phase | CBD | 0.29 | 0.01–0.57 | 0.11 | 0.010 |
PSP | 0.28 | 0.07–0.50 | 0.08 | <0.001 | ||
CERAD plaques | CBD | 0.50 | 0.01–0.98 | 0.19 | 0.011 | |
PSP | 0.43 | 0.14–0.72 | 0.11 | <0.001 | ||
Thal phase | CERAD plaques | CBD | 1.45 | 1.09–1.82 | 0.14 | <0.001 |
PSP | 1.05 | 0.83–1.27 | 0.09 | <0.001 | ||
FTD-Tau | Braak stage | CBD | −3.31 | −8.33 - 1.71 | 1.95 | 0.097 |
PSP | 1.47 | −1.92 - 4.86 | 1.32 | 0.267 | ||
Thal phase | CBD | 0.47 | −3.51 - 4.46 | 1.55 | 0.761 | |
PSP | 1.71 | −1.29 - 4.71 | 1.17 | 0.145 | ||
CERAD plaques | CBD | 0.73 | −6.13 - 7.60 | 2.67 | 0.785 | |
PSP | 1.00 | −3.15 - 5.16 | 1.61 | 0.535 |